-
admin
Posts
Brilliant Earth Releases Fifth Annual Mission Report, Celebrating Two Decades of Transforming the Jewelry Industry
SAN FRANCISCO, March 05, 2026 (GLOBE NEWSWIRE) — Brilliant Earth Group, Inc. (Nasdaq: BRLT), a global leader in ethically sourced fine jewelry, today released its...
Burlington Stores, Inc. Reports Fourth Quarter and Full Year 2025 Earnings
Q4 total sales grew 11%, and comparable store sales increased 4% Q4 net income was $310 million, and diluted EPS was $4.84 FY25 total sales grew 9%, and comparable store sales increased 2% FY25 net income was $610 million, and...
OLAPLEX Reports Fourth Quarter and Fiscal Year 2025 Results
NEW YORK, NY, March 05, 2026 (GLOBE NEWSWIRE) — Olaplex Holdings, Inc. (NASDAQ: OLPX) (“OLAPLEX” or the “Company”) today announced financial results for the fourth...
Teads Holding Co. Announces Fourth Quarter and Full Year 2025 Results
NEW YORK, March 05, 2026 (GLOBE NEWSWIRE) — Teads Holding Co. (Nasdaq: TEAD) (“Teads” or the “Company”) announced today financial results for the quarter and...
Invivyd Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Recent Business Highlights and DECLARATION Clinical Trial Updates
Achieved Q4 2025 PEMGARDA® (pemivibart) net product revenue of $17.2 million, representing 25% growth year-over-year and 31% growth quarter-over-quarter 2025 year-end cash and cash equivalents...
Invivyd Appoints Distinguished Physician and Scientist, Michael Mina, M.D., Ph.D. as Chief Medical Officer
Former assistant professor of epidemiology, immunology, and infectious disease at the Harvard T.H. Chan School of Public Health and pathology at Harvard Medical School and...
Erasca and Tango Therapeutics Enter into Clinical Collaboration to Evaluate Combination of ERAS-0015 and Vopimetostat
ERAS-0015, a pan-RAS molecular glue, will be evaluated in combination with PRMT5 inhibitor vopimetostat Tango will sponsor the clinical trial and Erasca will supply ERAS-0015...
Bioventus Announces Fourth Quarter and Full Year 2025 Financial Results
Q4 reported revenue of $157.9 million increased 2.8% and organic* revenue increased 10.0% Fourth quarter GAAP earnings of $0.21 per diluted share compared to $0.00...
Climb Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
Dosing completed in Phase 1 study of budoprutug subcutaneous formulation, with data expected in H1 2026 Budoprutug clinical trials ongoing in pMN, ITP, and SLE,...
Huawei Launches AI Data Platform to Bridge Models and Business Value
BARCELONA, Spain, March 5, 2026 /PRNewswire/ — At the Huawei Product & Solution Launch during MWC Barcelona 2026, Yuan Yuan, President of Huawei Data Storage...
